Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11747913 | 0.87 | TYR (0.39) | ALOX5ALDH1A1LMNA | |
| SCHEMBL8036449 | 0.79 | TYR (0.52) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL18242442 | 0.78 | CHRNA7 (0.42) | ACHETDP1CHRNA7ALOX5ALDH1A1 | |
| SCHEMBL4434585 | 0.77 | ACHE (0.47) | ACHETDP1CHRNA7ALOX5ALDH1A1 | |
| SCHEMBL31489555 | 0.77 | ACHE (0.47) | ACHETDP1CHRNA7ALOX5ALDH1A1 | |
| SCHEMBL1047188 | 0.77 | CYP1A2 (0.48) | ALOX5ALDH1A1LMNACYP2A6 | |
| SCHEMBL897929 | 0.77 | ACHE (0.47) | ACHETDP1CHRNA7ALOX5ALDH1A1 | |
| P-Cymene SCHEMBL1143 | 0.75 | ACHE (0.53) | ACHETDP1CHRNA7ALOX5LMNA | |
| SCHEMBL6546299 | 0.75 | ACHE (0.53) | ACHETDP1CHRNA7ALOX5ALDH1A1 | |
| SCHEMBL146509 | 0.75 | ESR1 (0.55) | ACHETDP1CHRNA7ALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117940155-A | Immunogenic composition, preparation method and application thereof | 清华大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-3348269-B1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFECTIVE VACCINE ADJUVANT | UNIV TSINGHUA (CN) | 2023-11-15 | — | — | EP | disclosed |
| CN-111225672-B | Mevalonate pathway inhibitor and pharmaceutical composition thereof | 清华大学 | 2023-09-29 | — | — | CN | disclosed |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2022-12-08 | — | — | US | disclosed |
| CN-114920744-A | Non-covalent BTK kinase inhibitor and biological application thereof | 中国药科大学 | 2022-08-19 | — | — | CN | disclosed |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | TSINGHUA UNIVERSITY (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20210008084-A1 | MEVALONATE PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | TSINGHUA UNIVERSITY (CN) | 2021-01-14 | — | — | US | disclosed |
| EP-3698797-A1 | MEVALONIC ACID PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | Tsinghua University (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | TSINGHUA UNIVERSITY (CN) | 2019-10-24 | — | — | US | disclosed |
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-22 | — | — | US | disclosed |
| WO-2013071697-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2013-05-23 | — | — | WO | disclosed |
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | KANEKA CORPORATION (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1942103-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | Kaneka Corporation (JP) | 2008-07-09 | — | — | EP | disclosed |
| EP-0882715-B1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA CHEMICAL IND CO LTD (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6339045-B1 | CAN BE USED IN A SMALL AMOUNT, SHOWING A GOOD SELECTIVITY BETWEEN CROP AND WEED, AND CAUSING NO PHYTOTOXICITY | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
| US-4742073-A | ANTIGLAUCOMA | BUNDGAARD HANS (DK) | 1988-05-03 | — | — | US | disclosed |
| EP-0106541-A2 | Pilocarpine prodrugs | Bundgaard, Hans (DK) | 1984-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321465-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | GGPS1, HMGCR, COASY | ACHE 897/4885TDP1 3476/4885CHRNA7 3525/4885 |
| US-10451967-B2 | Acid- and radical-generating agent and method for generating acid and radical | CBR1, HAO2, CBR3 | ACHE 4671/4885TDP1 3467/4885CHRNA7 2626/4885 |
| US-11382971-B2 | Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant | GGPS1, HMGCR, COASY | ACHE 931/4885TDP1 3503/4885CHRNA7 3558/4885 |
| US-20210008084-A1 | MEVALONATE PATHWAY INHIBITOR AND PHARMACEUTICAL COMPOSITION THEREOF | PDCD1, CD274, PDCD5 | ACHE 4655/4885TDP1 3364/4885CHRNA7 4533/4885 |
| US-20090275779-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BENZYLAMINE DERIVATIVE | SMS, SRM, ABHD5 | ACHE 1363/4885TDP1 4486/4885CHRNA7 3853/4885 |
| US-20220387584-A1 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | COASY, GGPS1, HMGCR | ACHE 927/4885TDP1 3524/4885CHRNA7 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.